Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201 in AL Amyloidosis

<div class="b2iNewsItemBodyDiv"><link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /><p>European Orphan Drug Designation ("ODD") qualifies NXC-201 for:</p> <ul><li>10 years of market exclusivity once authorized in the EU</li><li>Access to the EU centralized authorization procedure</li><li>Reduced fees for EU protocol assistance, marketing authorization applications, inspections before authorization, applications for changes to marketing...